/ EN
2026-06-30 00:00 United States Policy & Regulation Regulatory Approval Translated from EN

FDA Clears Universal Brain UB ERP System

Summary The FDA cleared Universal Brain's UB ERP System on June 30, 2026, finding it substantially equivalent under submission number K253767 through the traditional 510(k) pathway. The agency classifies it as Non-Normalizing Quantitative Electroencephalograph Software, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Event-related potentials are obtained by averaging EEG time-locked to stimuli; components such as P300 serve both clinical assessment and the classic paradigms behind noninvasive BCI spellers.
Why it matters Worth noting for the pathway more than the product: ERP analysis reached the US market as non-normalizing quantitative EEG software rather than as a device category of its own, which is the regulatory route BCI-adjacent signal tools are likely to keep taking.

BCIwiki (bciwiki.com) — Universal Brain received an FDA 510(k) decision of Substantially Equivalent for UB ERP System on June 30, 2026, under submission number K253767. The submission followed the Traditional 510(k) clearance pathway.

FDA lists the product under the device classification name Non-Normalizing Quantitative Electroencephalograph Software. It is a Class 2 device under regulation number 882.1400, assigned to the Neurology advisory committee. Event-related potentials are obtained by averaging EEG time-locked to stimuli; components such as P300 serve both clinical assessment and the classic paradigms behind noninvasive BCI spellers.

Compiled by BCIwiki from public sources

Sources · 1
Read original ↗
Suggest a correction Revisions · none / EN
© 2026 BCIwiki.com Digest Topics Tips Subscribe Revisions About